Emergent BioSolutions secures $29M in MCM product orders

Emergent BioSolutions (EBS) secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29M. The orders span several product offerings within Emergent’s medical countermeasures business, including countermeasures for smallpox, anthrax and botulism threats, and reflects the increasing priority governments are placing on defense and preparedness. This is the second procurement made this year by the same government. Emergent will receive approximately $26M in 2025, which is in addition to the more than $100M in sales already generated year to date for its MCM portfolio outside of the U.S.